Kathryn Haviland

President and Chief Executive Officer at Blueprint Medicines

Board

Since April 4, 2022

Age

48 years

Education

Holds a B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University and an M.B.A. from Harvard Business School.

Tenure

Joined BPMC in 2016 as Chief Business Officer, served as Chief Operating Officer from 2019 to April 3, 2022, and became President and CEO on April 04, 2022.

Also at Blueprint Medicines

Debra Durso-Bumpus

Chief People Officer

Philina Lee

Chief Commercial Officer

Ariel Hurley

Senior Vice President, Finance and Principal Accounting Officer

About

Kathryn Haviland is a seasoned executive with extensive experience in the biopharmaceutical industry. She joined Blueprint Medicines Corporation in 2016, initially serving as Chief Business Officer, before advancing to the role of Chief Operating Officer and then President and Chief Executive Officer on April 04, 2022.

Throughout her tenure at BPMC, she has played a pivotal role in guiding the company through significant organizational transitions, demonstrating expertise in corporate strategy, financial management, and business development.

Beyond her professional responsibilities at BPMC, she holds strong educational credentials with a B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University and an M.B.A. from Harvard Business School, which have bolstered her analytic and strategic capabilities.

$BPMC Performance Under Kathryn Haviland

Past Roles

Organization	Role	Date Range	Details
Blueprint Medicines Corporation (BPMC)	Chief Operating Officer	2019–2022	Served in this role prior to her appointment as President and CEO
Blueprint Medicines Corporation (BPMC)	Chief Business Officer	2016–2019	Held this position before transitioning to COO
Idera Pharmaceuticals, Inc.	Vice President, Rare Diseases and Oncology Program Leadership	2014–2015	Idera is focused on oncology and inflammation (now Aceragen, Inc.)
Sarepta Therapeutics, Inc.	Head of Commercial Development	2012–2014	Focused on rare diseases
PTC Therapeutics, Inc.	Executive Director of Commercial Development	2007–2012	Focused on small molecule drugs and gene therapy
Genzyme Corporation	Various corporate development and project management roles	2005–2007	Now a subsidiary of Sanofi

External Roles

Organization	Role	Date Range	Details
Fulcrum Therapeutics, Inc.	Chairperson and member of the Audit and Nominating and Corporate Governance Committees	Since 2018	N/A

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$782,250	Annual	Fixed annual salary for 2023
All Other Compensation	$13,200	Per 401(k) matching contribution schedule	Dollar value of matching contributions under the company’s 401(k) plan
Termination & Change-in-Control Compensation	Varies (up to $18,508,534)	Upon termination or change-in-control events	Includes severance payments, cash incentive payments, health care continuation, and acceleration of equity vesting under different scenarios

Performance Compensation

Data from FY 2023

Annual Performance-Based Cash Incentives for 2023

Metric	Value	Details
Target Payout ($)	$625,800	80% of base salary; set as the target for performance-based cash incentive
Maximum Payout ($)	$938,700	Capped at 150% of the target payout
Threshold	N/A	Not applicable for performance-based cash payments
Performance Weight (%)	50%	Relative weighting for corporate performance goals
Evaluation Period	Calendar Year 2023	Performance measured over 2023 based on corporate financial and operational results
Key Performance Metrics	Various	Includes global product revenue targets for AYVAKIT, global total revenue, achieving an operating loss equal to or better than 2022, and specific launch/approval milestones (e.g., FDA approval and EU CHMP positive opinion for indolent SM)
Grant Date	March 1, 2023	Grant date with compensation committee approval on February 15, 2023
Vesting/Payment Condition	No vesting; Cash payout	Cash incentive paid if Kathryn remains employed through the bonus payment date
Actual Cash Incentive Payment ($)	$719,670	Reflects the achievement of the set corporate performance goals

Additional Details

The performance compensation is solely based on corporate performance goals; there are no individual performance metrics applicable for the CEO.
The bonus structure does not involve vesting, as it is a cash payout determined after the evaluation period.